Results 211 to 220 of about 107,900 (262)
Some of the next articles are maybe not open access.
Current Opinion in Internal Medicine, 2006
The purpose of this review is to summarize new information regarding the use of selective inhibitors of the cyclooxygenase-2 enzyme, emphasizing recent developments regarding cardiovascular risk.Selective cyclooxygenase-2 inhibitors are as effective as nonselective nonsteroidal antiinflammatory drugs in relieving pain and inflammation but are ...
Christopher J, Hawkey, Paul J, Fortun
openaire +2 more sources
The purpose of this review is to summarize new information regarding the use of selective inhibitors of the cyclooxygenase-2 enzyme, emphasizing recent developments regarding cardiovascular risk.Selective cyclooxygenase-2 inhibitors are as effective as nonselective nonsteroidal antiinflammatory drugs in relieving pain and inflammation but are ...
Christopher J, Hawkey, Paul J, Fortun
openaire +2 more sources
Cyclooxygenase-2 Inhibition and Coagulation
Journal of Cardiovascular Pharmacology, 2006Selective inhibitors of cyclooxygenase-2 (COX-2) have come under scrutiny because of a possibly increased thrombotic risk observed in retrospective studies and comparatively small cancer trials. Indeed, inhibition of COX-2 may favor a prothrombotic environment by suppressing endothelial prostacyclin synthesis while leaving COX-1-dependent platelet ...
Steffel, J +3 more
openaire +4 more sources
Cyclooxygenase-2 in oncogenesis
Clinica Chimica Acta, 2011Compelling experimental and clinical evidence supports the notion that cyclooxygenase-2, the inducible isoform of cyclooxygenase, plays a crucial role in oncogenesis. Clinical and epidemiological data indicate that aberrant regulation of cyclooxygenase-2 in certain solid tumors and hematological malignancies is associated with adverse clinical outcome.
openaire +2 more sources
2001
Publisher Summary This chapter deals with aspects of the discovery and development of Cyclooxygenase-2 (Cox-2) inhibitors, which, in the case of rofecoxib, resulted from efforts that were initiated in July of 1992 and culminated in the launch of the drug in the United States in June of 1999. Nonsteroidal antiinflammatory drugs (NSAIDs) have long been
A S, Nies, M J, Gresser
openaire +2 more sources
Publisher Summary This chapter deals with aspects of the discovery and development of Cyclooxygenase-2 (Cox-2) inhibitors, which, in the case of rofecoxib, resulted from efforts that were initiated in July of 1992 and culminated in the launch of the drug in the United States in June of 1999. Nonsteroidal antiinflammatory drugs (NSAIDs) have long been
A S, Nies, M J, Gresser
openaire +2 more sources
Current Pharmaceutical Design, 2003
In mammalian cells, eicosanoid biosynthesis is usually initiated by the activation of phospholipase A(2) and the release of arachidonic acid from membrane phospholipids in response to the interaction of a stimulus with a receptor on the cell surface. Arachidonic acid is subsequently transformed by the enzyme cyclooxygenase (COX) to prostaglandins (PGs)
openaire +2 more sources
In mammalian cells, eicosanoid biosynthesis is usually initiated by the activation of phospholipase A(2) and the release of arachidonic acid from membrane phospholipids in response to the interaction of a stimulus with a receptor on the cell surface. Arachidonic acid is subsequently transformed by the enzyme cyclooxygenase (COX) to prostaglandins (PGs)
openaire +2 more sources
Cyclooxygenase-2 and inflammation in atherosclerosis
Current Opinion in Pharmacology, 2004By regulating the production of eicosanoids, cyclooxygenase (COX) modulates processes contributing to atherosclerosis and thrombosis, including platelet aggregation and the local inflammatory response. COX-2, a key mediator of inflammation, is upregulated in activated monocyte/macrophages, suggesting that COX-2 inhibition might reduce atherogenesis ...
MacRae F, Linton, Sergio, Fazio
openaire +2 more sources
Cyclooxygenase-2 as a therapeutic target
Inflammation Research, 1998Cyclooxygenase (COX)-2 is the predominant COX isoform present at sites of inflammation, and produces prostaglandins (PG) that cause swelling and pain. However, in situations where the release of protective PGs by COX-1 has been lost, the induction of COX-2 may compensate and reduce inflammatory responses.
J A, Mitchell, T W, Evans
openaire +2 more sources
Cyclooxygenase‐2 and gastric carcinogenesis
APMIS, 2003Epidemiological studies have shown that the use of nonsteroid anti‐inflammatory drugs (NSAIDs) is associated with reduced risk of gastric cancer. The best‐known target of NSAIDs is the cyclooxygenase (Cox) enzyme. Two Cox genes have been cloned, of which Cox‐2 has been connected with gastric carcinogenesis.
Kirsi, Saukkonen +9 more
openaire +2 more sources
THE ROLE OF CYCLOOXYGENASE-2 IN INFLAMMATION
American Journal of Therapeutics, 1995Prostaglandins (PGs) can be synthetized via two isoforms of cyclooxygenase (COX). COX-1 is constitutively expressed in normal tissues, and its activity represent the normal physiological output of PGs. In inflammatory states, the newly discovered COX-2 is rapidly induced, and its activity accounts for the large amounts of PGs seen in inflammation.
Jaime L., Masferrer +6 more
openaire +2 more sources
Cyclooxygenase‐2 in cancer: A review
Journal of Cellular Physiology, 2018AbstractCyclooxygenase‐2 (COX‐2) is frequently expressed in many types of cancers exerting a pleiotropic and multifaceted role in genesis or promotion of carcinogenesis and cancer cell resistance to chemo‐ and radiotherapy. COX‐2 is released by cancer‐associated fibroblasts (CAFs), macrophage type 2 (M2) cells, and cancer cells to the tumor ...
Nasser Hashemi Goradel +4 more
openaire +2 more sources